CME vs NDAQ

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

CME

32.8
AI Score
VS
NDAQ Wins

NDAQ

40.9
AI Score

Investment Advisor Scores

CME

Oct 22, 2026
33score
Recommendation
AVOID NEW MONEY

NDAQ

Oct 22, 2026
41score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CME NDAQ Winner
Forward P/E 21.9298 23.6407 CME
PEG Ratio 4.7092 1.7643 NDAQ
Revenue Growth 0.8% 14.9% NDAQ
Earnings Growth 2.5% 14.1% NDAQ
Tradestie Score 32.8/100 40.9/100 NDAQ
Profit Margin 63.4% 35.0% CME
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation AVOID NEW MONEY HOLD Tie

Relative Price Performance (Last 90 Days)

CME 1M: +13.0% · 3M: +19.8% NDAQ 1M: +8.2% · 3M: +12.2%

Current Technical Phase

CME

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.0% over 20 days), RSI 78

RSI (14): 78.4 · Price: $305.98

NDAQ

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 74

RSI (14): 73.9 · Price: $103.30

Fundamentals Snapshot

Metric CME NDAQ
Market Cap — —
Forward P/E 23.4 22.1
Trailing P/E 25.1 27.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 1.0% 1.0%
Operating Margin 0.7% 0.5%
EPS 11.79 3.48
Dividend Yield 0.02% 0.01%

Frequently Asked Questions

Based on our detailed analysis, NDAQ is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.